The first organometallic antioestrogens and their antiproliferative effects

a) MacGregor J.I., Jordan V.C., Pharmacol. Rev. 50 (1998) 151; b) Legros N., Jin L., Leclercq G., Cancer, Chemother. Pharmacol. 39 (1997) 380; c) Nayfield S.G., Karp J.E., Ford L.G., Dorr F.A., Kramer B.S., J. Natl. Cancer Int. 23 (1991) 1450. Magarian, 1994, Curr. Med. Chem, 1, 61, 10.2174/0929867301666220210212635 a) Grese T.A., Cho S., Finley D.R. et al., J. Med. Chem. 40 (1997) 146; b) Levenson A.S., Jordan V.C., Canc. Res. 58 (1998) 1872; c) Jiang S.Y., Parker C.J., Jordan V.C., Breast Cancer Res. Treat. 26 (1993) 139; d) Parker M.G., Breast Cancer Res. Treat. 26 (1993) 131. a) Top S., Tang J., Vessières A., Carrez D., Provot C., Jaouen G., J.C.S. Chem. Commun. (1996) 955; b) Top S., Dauer B., Vaissermann J., Jaouen G., J. Organomet. Chem. 541 (1997) 355. a) Gallo M.A.; Kaufman D. Semin. Oncol. 24 (1997) S1–71; b) Paech K., Webb P., Kuiper G.G.J.M., Nilsson S., Gustafsson J-Å., Kushner P.J., Scanlan T.S., Science 277 (1997) 1508. a) Köpf-Maier P., Eur. J. Clin. Pharmacol. 47 (1994) 1; b) Houlton A., Roberts R.M.G., Silver J., J. Organomet. Chem. 418 (1991) 107. Top S. et al., manuscript in preparation. Brzozowski, 1997, Nature, 389, 753, 10.1038/39645 Jin, 1998, Cancer Chemother. Pharmacol., 41, 339, 10.1007/s002800050748 Hardcastle, 1996, J. Med. Chem., 39, 999, 10.1021/jm9505472 Vessières, 1988, Biochemistry, 27, 6659, 10.1021/bi00418a003 Top, 1995, J. Am. Chem. Soc., 117, 8372, 10.1021/ja00137a010 Leclercq, 1983, J. Steroid Biochem., 19, 75, 10.1016/S0022-4731(83)80009-0 Faye, 1983, Proc. Natl. Acad. Sci. USA, 80, 3158, 10.1073/pnas.80.11.3158 Van Roy, 1990, Int. J. Cancer, 46, 522, 10.1002/ijc.2910460332 Kuiper, 1996, Proc. Natl. Acad. Sci. USA, 93, 5925, 10.1073/pnas.93.12.5925 Vladusic, 1998, Canc. Res., 58, 210 Colletta, 1994, Breast Cancer Res. Treat., 31, 5, 10.1007/BF00689672 Jordan, 1980, Eur. J. Cancer, 16, 239, 10.1016/0014-2964(80)90156-5